Trivant Custom Portfolio Group
VRTX icon

Trivant Custom Portfolio Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Trivant Custom Portfolio Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$965K Buy
+1,845
New +$945K 0.5% 57
2024
Q1 		– Sell
-100
Closed -$40.7K – 195
2023
Q4 		$40.7K Hold
100
– – 0.03% 116
2023
Q3 		$34.8K Hold
100
– – 0.03% 109
2023
Q2 		$35.2K Buy
+100
New +$33.7K 0.02% 126

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Trivant Custom Portfolio Group's VRTX Position: Q3 2026 in Review

Trivant Custom Portfolio Group opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 1,845 shares worth $965K. The stake represents 0.5% of the portfolio and ranks #57 among its holdings. This is a return to the name: Trivant Custom Portfolio Group previously reported a position in VRTX as recently as Q4 2023.

Trivant Custom Portfolio Group first reported a position in VRTX in Q2 2023 and has held it in 4 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Trivant Custom Portfolio Group held 1,845 shares of Vertex Pharmaceuticals worth $965K as of Q3 2026.
  • Vertex Pharmaceuticals was a new Trivant Custom Portfolio Group position in Q3 2026.
  • Vertex Pharmaceuticals made up 0.5% of Trivant Custom Portfolio Group's portfolio in Q3 2026, its #57 holding.
  • Trivant Custom Portfolio Group first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 4 quarters since.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Trivant Custom Portfolio Group's 13F filing for Q3 2026, filed 12 Nov 2026.